Interaction of β-L-2',3'-dideoxy-2',3'-didehydro-5-fluoro-CTP with human immunodeficiency virus-1 reverse transcriptase and human DNA polymerases: Implications for human immunodeficiency virus drug design

Molecular Pharmacology

Volumn 53, Issue 5, 1998, Pages 801-807

  Kukhanova, Marina ^a   Li, Xiuyan ^b   Chen, Shu Hui ^b   King, Ivan ^b   Doyle, Terrence ^b   Prusoff, William ^a   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Vion Pharmaceuticals Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXY 5 FLUOROCYTIDINE; ANTIVIRUS AGENT; DNA POLYMERASE; ELVUCITABINE; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; ZALCITABINE;

ARTICLE; CONCENTRATION RESPONSE; DNA STRAND; DRUG DESIGN; DRUG STRUCTURE; ENZYME ANALYSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INHIBITION KINETICS; PRIORITY JOURNAL; VIRUS INHIBITION;

ANTI-HIV AGENTS; DNA REPLICATION; DNA-DIRECTED DNA POLYMERASE; DRUG DESIGN; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; KINETICS; REVERSE TRANSCRIPTASE INHIBITORS; ZALCITABINE;

EID: 0031780614     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Beancage SL (1993) Oligodeoxynucleotides synthesis, in Protocols for Oligonucleotides and Analogs (Agrawal S, ed) p. 34, Humana Press, Totowa, NJ.
2. Beard WA and Wilson SH (1993) Kinetic analysis of template-primer interaction with recombinant forms of HIV-1 reverse transcriptase. Biochemistry 32:9745-9753.
3. Belleau B, Dixit D, Nguyen-Ba N, and Kraus JL (1989) Fifth International Conference on AIDS; 1989 Jun 4-9; Montreal, Canada. p. 515.
4. Birnbaum GI, Giziewicz J, Lin TS, and Prusoff WH (1989) Structural features of 2′,3′-dideoxy-2′3′-didehydrocytidine, a potent inhibitor of the HIV (AIDS) virus. Nucleosides Nucleotides 8:1259-1269.
5. Boosalis MS, Mosbaugh DW, Hamatake R, Sugino A, Kunkel TA, and Goodman MF (1989) Kinetic analysis of base substitution mutagenesis by transient misalignment of DNA and by miscoding. J Biol Chem 264:11360-11366.
6. Chang CN, Skalski V, Zhou JH, and Cheng YC (1992) Biochemical pharmacology of (+)- and (-)- 2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 267:22414-22420.
7. Chen CH and Cheng YC (1989) Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem 264:11934-11937.
8. Chen SH, Li X, Li J, Niu C, Carmichael E, and Doyle TW (1997) Stereoselective synthesis of β-L-2′,3′-dideoxy-2',3'-didehydro-5-fluorocytidine and β-L-2′,3′-dideoxy-5-fluorocytidine. J Org Chem 62:3449-3452.
9. Copeland WC, Chen MS, and Wang TC (1992) Human DNA polymerases alpha and beta to incorporate anti-HIV deoxynucleotides into DNA. J Biol Chem 267:21459-21464.
10. Doong SL, Tsai CN, Schinazi RF, Liotta DC, and Cheng YC (1991) Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 88:8495-8499.
11. Dutschman GE, Bridges EG, Liu SH, Gullen E, Guo X, Kukhanova M, and Cheng YC (1998) 2′,3′-Dideoxy-2′,3′-didehydro-β-L(-)-5- fluorocytidine, its metabolism, animal toxicity and combination with clinically approved anti-HIVβ-D(+)nucleoside analogs. Antimicrob Agents Chemother, in press.
12. Dyatkina N, Minassian S, Kukhanova M, Krayevsky A, von Janta-Lipinsky M, Chidgeavadze Z, Beabealashvilli R (1987) Properties of 2′,3′-dideoxy-2′,3′-dehydrothymidine 5′-triphosphate in terminating DNA synthesis catalyzed by several different DNA polymerases. FEBS Lett 219:151-155.
13. Eriksson S, Xu B, and Clayton DA (1995) Efficient incorporation of anti-HIV deoxynucleotides by recombinant yeast mitochondrial DNA polymerase. J Biol Chem 270:18929-18934.
14. Faray A, Schinazi RF, Joudawskis A, Lesnikowski Z, McMillan A, Morrow CD, and Somadossi JP (1997) Effect of β-D-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine 5′-triphosphate (β-D- D4FC-TP) and its β-L-enantiomer 5′-triphosphate (β-L-D4FC-TP) on viral DNA polymerases. Antivir Res 34:A66.
15. Ferrin LJ and Mildvan AS (1985) Nuclear overhauser effect studies of the conformations and binding site environments of deoxynucleoside triphosphate substrates bound to DNA polymerase I and its large fragment. Biochemistry 24:6904-6913.
16. Ferrin L J and Mildvan AS (1986) NMR studies of conformations and interactions of substrates and ribonucleotide templates bound to the large fragment of DNA polymerase I. Biochemistry 25:6904-6913.
17. Gurskaya GV, Bochkarev AV, Tsapkina EN, Zhdanov AS, and Krayevsky AA (1991) Structure and biological activity correlation for some nucleoside analogues-inhibitors of reproduction of human immunodeficiency virus (HIV-1). Nucleic Acids Symp Ser 24:241.
18. Harte WE Jr, Starrett JE Jr, Martin JC, and Mansuri MM (1991) Structural studies of the anti-HIV agent 2′,3′-didehydro-2′,3′-dideoxythymidine (D4T) Biochem Biophys Res Commun 175:298-304.
19. Hoard DE and Ott DG (1965) Conversion of mono- and oligodeoxynucleotides to 5′-triphosphates. J Am Chem Soc 87:1785-1788.
20. Krayevsky A and Watanabe K (1993) in Modified Nucleosides with Conformationally Restricted Sugar Moiety (Mirzabekov A, ed). pp. 136-154, Bioinform, Moscow.
21. Kukhanova M K, Liu SH, Mozzherin D, Lin TS, Chu CK, and Cheng YC (1995) L- and D- enantiomers of 2′,3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases. J Biol Chem 270:23055-23059.
22. Lin TS, Luo MZ, Liu MC, Pai SB, Dutschman GE, and Cheng YC (1994a) Antiviral activity of 2′,3′-dideoxy-β-L-fluorocytidine (β-L-FddC) and 2′,3′-dideoxy-β-L-cytidine (β-L-ddC against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem Pharmacol 47:171-174.
23. Lin TS, Luo MZ, Liu MC, Pai SB, Dutschman GE, and Cheng YC (1994b) Synthesis and biological evaluation of 2′,3′-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV) J Med Chem 37:798-803.
24. Lin TS, Luo MZ, Zhu YL, Gullen E, Dutschman GE, and Cheng YC (1996) Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-β-L-cytidine (β-L-d4C) and 2′,3′-dideoxy-2′,3′-didehydro-β- L-5-fluorocytidine (β-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. J Med Chem 39:1757-1759.
25. Mendelman LV, Petrushka J, and Goodman MF (1990) Base mispair extension kinetics. comparison of DNA polymerase α and reverse transcriptase. J Biol Chem 265:2338-2346.
26. Ono K, Nakane H, Herdewijn P, Balzarini J, and De Clercq E (1989) Differential inhibitory effects of several pyrimidine 2′,3′-dideoxynucleoside 5′-triphosphates on the activities of reverse transcriptase and various cellular DNA polymerases. Mol Pharmacol 35:578-583.
27. Sambrook J, Fritch EF, and Manniatis T (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., pp. 1054-1061, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
28. Sanger FS, Nicklen S, and Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74:5463-5467.
29. St.Clair MH, Richards CA, Spector T, Weinhold KJ, Miller WH, Langlois AJ, and Furman PA (1987) 3′-azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 31:1972-1977.
30. Ueno T and Mitsuya H (1997) Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2′,3′-dideoxynucleotide analogs using the single-nucleotide incorporation assay. Biochemistry 36:1092-1099.
31. Van Roey P and Chu CK (1992) The crystal and molecular structure of the complex of 2′,3′-didehydro-2′,3′-dideoxyguanosine with pyridine. Nucleosides Nucleotides 11:1229-1239.
32. Wilson EJ, Aulabaugh A, Caligan B, McPherson S, Wakefield JK, Jablonski S, Morrow CD, Reardon JE, and Furman PA (1996) Human immunodeficiency virus type-1 reverse transcriptase. contribution of met-184 to binding of nucleoside 5′-triphosphate. J Biol Chem 271:13656-13662.